Tensive has appointed Peter Crosby as Chairman of its Board of Directors as the company advances toward regulatory approval and commercialization of its REGENERA™/SOFTAG™ bioresorbable breast reconstruction scaffold.
Crosby brings more than 40 years of medtech leadership experience, having helped bring multiple implantable medical devices through CE marking, FDA approval, and commercial launch. He previously led companies including Mainstay Medical, taking its neurostimulation technology through regulatory approval and public listing.
Get the latest in Medical Aesthetics in our weekly ValuraNova Pulse. Sign up now.
The appointment comes as Tensive prepares for pivotal regulatory milestones for REGENERA™/SOFTAG™, with first CE mark approval expected in early 2027. The scaffold is designed to provide a natural breast reconstruction option following lumpectomy by supporting the regrowth of the patient’s own tissue while gradually being absorbed by the body.
Tensive CEO Sanjay Kakkar said:
“Peter’s strategic insight and deep governance experience will be crucial advantages as we advance our first device into regulatory processes for marketing approval and commercialization in the U.S. and Europe.”
Crosby added:
“I was struck by the strength of the data behind REGENERA™/SOFTAG™ and the clear unmet need it addresses.”
The company’s technology is supported by positive pivotal-trial and first-in-human results, positioning Tensive for its transition toward commercial-stage development in breast reconstruction and tissue marking.
Read the full story here.
